An Indian effort towards affordable drugs: "Generic to designer drugs"

Biotechnology Journal

Volumn 4, Issue 3, 2009, Pages 348-360

  Taneja, Bhupesh ^a   Yadav, Jyoti ^a   Chakraborty, Tushar K ^b   Brahmachari, Samir K ^a,c  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Drug development; Indian generics; Open source; Target discovery

Indexed keywords

ANALGESIC AGENT; ANTIGLAUCOMA AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CAPTOPRIL; CARDIOVASCULAR AGENT; CELIPROLOL; CISAPRIDE; DORZOLAMIDE; EPIBATIDINE; ETOPOSIDE; GENERIC DRUG; IRINOTECAN; LAMIVUDINE; NATURAL PRODUCT; NEVIRAPINE; PEPTIDOMIMETIC AGENT; RANITIDINE; SAQUINAVIR; SMALL INTERFERING RNA; STAVUDINE; UNINDEXED DRUG; ZANAMIVIR; ZIDOVUDINE; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENOMICS; GLAUCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INDIA; INFLUENZA; MYCOBACTERIUM TUBERCULOSIS; PATENT; PRIORITY JOURNAL; PROTEOMICS;

DRUG DESIGN; DRUG INDUSTRY; DRUGS, GENERIC; FINANCING, GOVERNMENT; HUMANS; INDUSTRY; MODELS, ECONOMIC; PRIVATE SECTOR; RESEARCH SUPPORT AS TOPIC; RNA, SMALL INTERFERING; SOFTWARE; TUBERCULOSIS;

EID: 64549134748     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200900031     Document Type: Article

References (48)

1. Hopkins, A. L., Groom, C. R., The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
2. Russ, A. P., Lampel, S., The druggable genome: An update. Drug Discov. Today 2005, 10, 1607-1610.
3. Agarwal, S. P., Gupta, A., Ashwani, Dayal, R., Technology transfer perspectives in globalising India (drugs and pharmaceuticals and biotechnology). J. Technol. Transfer 2007, 32, 397-423.
4. Department of Chemicals and Petrochemicals, Annual Report, 2007-2008.
5. Thomas, J. J., Innovation in India and China: Challenges and prospects in pharmaceuticals and biotechnology, in: Parayil, G., D'Costa, A. P. (Eds.), The new Asian Innovation Dynamics. China and India in perspective, Palgrave Macmillan, London; 2009, pp. 110-137.
6. Maggon, K., New drug discovery and development in India. Drug News Perspect.s 2003 16 (Suppl. A), 1-19.
7. Singh, S. K., Maithal, K., Balaram, H., Balaram, P., Synthetic peptides as inactivators of multimeric enzymes: Inhibition of Plasmodium falciparum triosephosphate isomerase by interface peptides. FEBS Lett. 2001 501, 19-23.
8. Sudarslal, S., Majumdar, S., Ramasamy, P., Dhawan, R. et al., Sodium channel modulating activity in a delta-conotoxin from an Indian marine snail. FEBS Lett. 2003, 553, 209-212.
9. Kundu, B., Srinivasan, T., Kesarwani, A. P., Kavishwar, A. et al., Identification of novel antifungal nonapeptides through the screening of combinatorial peptide libraries based on a hexapeptide motif. Bioorg. Med. Chem. Lett. 2002, 12, 1473-1476.
10. Krishnakumari, V., Singh, S., Nagaraj, R., Antibacterial activities of synthetic peptides corresponding to the carboxyterminal region of human beta-defensins 1-3. Peptides 2006, 27, 2607-2613.
11. Yadav, S. P., Ahmad, A., Pandey, B. K., Verma, R. et al., Inhibition of lytic activity of E. coli toxin hemolysin E against human red blood cells by a leucine zipper peptide and understanding the underlying mechanism. Biochemistry 2008, 47, 2134-2142.
12. Clark, D. E., Newton, C. G., Outsourcing lead optimization - The quiet revolution. Drug Discov. Today 2004, 9, 492-500.
13. Verma, A., Halder, K., Halder, R., Yadav, V. K. et al., Genome-wide computational and expression analyses reveal G-quadruplex DNA motifs as conserved cis-regulatory elements in human and related species. J. Med. Chem. 2008 51, 5641-5649.
14. Thakur, R. K., Kumar, P., Halder, K., Verma, A. et al., Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic Acids Res. 2009, 37, 172-183.
15. Prakash, T., Khandelwal, M., Dasgupta, D., Dash, D. et al., CoPS: Comprehensive Peptide Signature database. Bioinformatics 2004, 20, 2886-2888.
16. Prakash, T., Ramakrishnan, C., Dash, D., Brahmachari, S. K., Conformational analysis of invariant peptide sequences in bacterial genomes. J. Mol. Biol. 2005, 345, 937-55.
17. Scaria, V., Hariharan, M., Pillai, B., Maiti, S. et al., Host-virus genome interactions: macro roles for microRNAs. Cell. Microbiol. 2007, 9, 2784-2794.
18. Vijayan, M., Peanut lectin crystallography and macromolecular structural studies in India. J. Biosci. 2007, 32, 1059-1066.
19. Vijayan, M., Macromolecular crystallography in India. A historical overview. J. Indian Instit. Sci. 2007, 87, 261-277.
20. Singh, N., Somvanshi, R. K., Sharma, S., Dey, S. et al., Structural elements of ligand recognition site in secretory phospho-lipase A2 and structure-based design of specific inhibitors. Curr. Top. Med. Chem. 2007, 7, 757-764.
21. Sekar, K., Eswaramoorthy, S., Jain, M. K., Sundaralingam, M., Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol. Biochemistry 1997, 36, 14186-14191.
22. Chandra, V., Jasti, J., Kaur, P., Dey, S. et al., Crystal structure of a complex formed between a snake venom phospholipase A(2) and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J. Biol. Chem. 2002, 277, 41079-41085.
23. Jain, D., Kaur, K., Sundaravadivel, B., Salunke, D. M., Structural and functional consequences of peptide-carbohydrate mimicry. Crystal structure of a carbohydrate-mimicking peptide bound to concanavalin A. J. Biol. Chem. 2000, 275, 16098-16102.
24. Velanker, S. S., Ray, S. S., Gokhale, R. S., Suma, S. et al., Triosephosphate isomerase from Plasmodium falciparum: The crystal structure provides insights into antimalarial drug design. Structure 1997 5, 751-761.
25. Parthasarathy, S., Balaram, H., Balaram, P., Murthy, M. R., Structures of Plasmodium falciparum triosephosphate isomerase complexed to substrate analogues: Observation of the catalytic loop in the open conformation in the ligand-bound state. Acta Crystallogr. D Biol. Crystallogr. 2002 58, 1992-2000.
26. Eaazhisai, K., Balaram, H., Balaram, P., Murthy, M. R., Structures of unliganded and inhibitor complexes of W168F, a Loop6 hinge mutant of Plasmodium falciparum triosephosphate isomerase: Observation of an intermediate position of loop6. J. Mol. Biol. 2004, 343, 671-684.
27. Eaazhisai, K., Jayalakshmi, R., Gayathri, P., Anand, R.P. et al., Crystal structure of fully ligated adenylosuccinate synthetase from Plasmodium falciparum. J. Mol. Biol. 2004, 335, 1251-1264.
28. Surolia, N., Surolia, A., Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7:167-173.
29. Suguna, K., Surolia, A., Surolia, N., Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum. Biochem. Biophys. Res. Commun. 2001, 283, 224-228.
30. Kesavulu, M. M., Prakasha Gowda A. S., Ramya, T. N., Surolia, N. et al., Plasmepsin inhibitors: Design, synthesis, inhibitory studies and crystal structure analysis. J. Pept. Res. 2005, 66, 211-219.
31. Pillai, B., Kannan, K. K., Bhat, S. V., Hosur, M. V., Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction. Acta Crystallogr. D Biol. Crystallogr. 2004, 60, 594-596.
32. Das, A., Rao, D. R., Hosur, M.V., X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir. Protein Pept. Lett. 2007, 14, 565-568.
33. Bihani, S., Das, A., Prashar, V., Ferrer, J. L. et al., X-ray structure of HIV-1 protease in situ product complex. Proteins 2009, 74, 594-602.
34. Datta, S., Prabu, M. M., Vaze, M. B., Ganesh, N. et al., Crystal structures of Mycobacterium tuberculosis RecA and its complex with ADP-AlF(4): Implications for decreased ATPase activity and molecular aggregation. Nucleic Acids Res. 2000 28, 4964-4973.
35. Kaushal, P. S., Talawar, R. K., Krishna, P. D., Varshney, U. et al., Unique features of the structure and interactions of mycobacterial uracil-DNA glycosylase: Structure of a complex of the Mycobacterium tuberculosis enzyme in comparison with those from other sources. Acta Crystallogr. D Biol. Crystallogr. 2008 64, 551-560.
36. Das, S., Kumar, P., Bhor, V., Surolia, A. et al., Invariance and variability in bacterial PanK: A study based on the crystal structure of Mycobacterium tuberculosis PanK. Acta Crystallogr. D Biol. Crystallogr. 2006, 62, 628-638.
37. Qamra, R., Prakash, P., Aruna, B., Hasnain, S. E. et al., The 2.15 Å crystal structure of Mycobacterium tuberculosis chorismate mutase reveals an unexpected gene duplication and suggests a role in host-pathogen interactions. Biochemistry 2006, 45, 6997-7005.
38. Srivastava, S. K., Dube, D., Tewari, N., Dwivedi, N. et al., Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I. Nucleic Acids Res. 2005, 33, 7090-7101.
39. Tripathi, S. M., Ramachandran, R., Direct evidence for a glutamate switch necessary for substrate recognition: crystal structures of lysine epsilon-aminotransferase (Rv3290c) from Mycobacterium tuberculosis H37Rv. J. Mol. Biol. 2006, 362, 877-86.
40. Sankaranarayanan, R., Saxena, P., Marathe, U. B., Gokhale, R. S. et al., A novel tunnel in mycobacterial type III polyketide synthase reveals the structural basis for generating diverse metabolites. Nat. Struct. Mol. Biol. 2004, 11, 894-900.
41. Selvaraj, M., Roy, S., Singh, N. S., Sangeetha, R. et al., Structural plasticity and enzyme action: crystal structures of Mycobacterium tuberculosis peptidyl-tRNA hydrolase. J. Mol. Biol. 2007, 372, 186-193.
42. Pulavarti, S.V., Jain, A., Pathak, P. P., Mahmood, A. et al., Solution structure and dynamics of peptidyl-tRNA hydrolase from Mycobacterium tuberculosis H37Rv. J. Mol. Biol. 2008, 378, 165-177.
43. Singh S., India takes an open source approach to drug discovery. Cell 2008, 133, 201-203.
44. Indian Genome Variation Consortium, Genetic landscape of the people of India: A canvas for disease gene exploration. J. Genet. 2008, 87, 3-20.
45. Kukreti, R., Bhatnagar, P., Rao, C., Gupta, S. et al., Beta (2)-andrenergic receptor polymorphism and response to salbutamol among Indian asthamatics. Pharmacogenomics 2005, 6, 399-410.
46. Illi, A., Kampman, O., Hänninen, K., Anttila, S. et al., Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 2007, 22, 211-215.
47. Gupta, M., Bhatnagar, P., Grover, S., Kaur, H. et al., Association studies of catechol-O-methyl transferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009 (in press).
48. Department of Scientific and Industrial Research, Annual Report, 2007-2008.